A Phase I and Pharmacodynamic Study of the Histone deacetylase inhibitor Belinostat plus Azacitidine in Advanced Myeloid Neoplasia

BACKGROUND: We hypothesized that targeting two mechanisms of epigenetic silencing would be additive or synergistic with regard to expression of specific target genes. The primary objective of the study was to establish the maximum tolerated dose (MTD) of belinostat in combination with a fixed dose o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Invest New Drugs
Autori principali: Odenike, Olatoyosi, Halpern, Anna, Godley, Lucy A., Madzo, Jozef, Karrison, Theodore, Green, Margaret, Fulton, Noreen, Mattison, Ryan J., Yee, Karen. W. L., Bennett, Meghan, Koval, Gregory, Malnassy, Gregory, Larson, Richard A., Ratain, Mark J., Stock, Wendy
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390421/
https://ncbi.nlm.nih.gov/pubmed/25483416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0194-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi